Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harrow Inc (NQ: HROW )

56.98 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 56.98
Bid (Size) 55.00 (4)
Ask (Size) 58.00 (1)
Prev. Close 56.98
Today's Range 56.98 - 56.98
52wk Range 7.600 - 59.23
Shares Outstanding 35,482,944
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
From Harrow, Inc.
Via Business Wire
The Analyst Landscape: 4 Takes On Harrow
Via Benzinga

Performance

YTD
+376.82%
+376.82%
1 Month
+28.22%
+28.22%
3 Month
+132.76%
+132.76%
6 Month
+452.13%
+452.13%
1 Year
+302.97%
+302.97%

More News

Read More
Harrow Relaunches TRIESENCE®
From Harrow, Inc.
Via Business Wire
Harrow Announces Nashville Expansion
From Harrow, Inc.
Via Business Wire
Navigating 5 Analyst Ratings For Harrow
Via Benzinga
Harrow to Present at Three Investor Conferences in September in New York
From Harrow, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
HROW Stock Earnings: Harrow Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Harrow Announces Second Quarter 2024 Financial Results
From Harrow, Inc.
Via Business Wire
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
From Harrow, Inc.
Via Business Wire
Harrow to Attend 2024 ASRS Annual Meeting
From Harrow, Inc.
Via Business Wire
Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products
From Harrow, Inc.
Via Business Wire
Top 3 Health Care Stocks That May Crash This Quarter
Via Benzinga
HROW Stock Earnings: Harrow Beats EPS, Beats Revenue for Q2 2023
Via InvestorPlace
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Harrow Provides TRIESENCE® Relaunch Update
From Harrow, Inc.
Via Business Wire
The Top 7 Growth Stocks to Buy and Hold Until 2030
Via InvestorPlace
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
From Harrow, Inc.
Via Business Wire
3 Stocks Insiders are Buying That Should be on Your Radar
Via MarketBeat
Harrow to Present at Two Investor Conferences in May
From Harrow, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.